AnaptysBio
ANAB
122 hedge funds and large institutions have $721M invested in AnaptysBio in 2021 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 25 increasing their positions, 50 reducing their positions, and 16 closing their positions.
15% more capital invested
Capital invested by funds: $629M → $721M (+$92.2M)
0% more funds holding
Funds holding: 122 → 122 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 16
5.05% less ownership
Funds ownership: 106.62% → 101.57% (-5%)
32% less call options, than puts
Call options by funds: $1.43M | Put options by funds: $2.11M
50% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 50
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$9.59M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$8.85M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.79M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$2.67M |
| 5 |
Millennium Management
New York
|
+$2.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$11.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$10.5M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$9.13M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$6.35M |
| 5 |
BlackRock
New York
|
-$5.85M |
ANAB Hedge Fund Activity: Q2 2021 in Review
122 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q2 2021, worth a combined $721M — up 15% from $629M a quarter earlier.
Fund positioning in ANAB was balanced in Q2 2021: 16 funds opened new positions, 16 closed out, 25 added to existing stakes and 50 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $9.59M. The largest seller was State Street, cutting an estimated $11.5M.
- 122 institutional investors held AnaptysBio (ANAB) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $721M of AnaptysBio stock for Q2 2021, up 15% quarter-over-quarter.
- 16 funds opened new AnaptysBio positions in Q2 2021 and 16 closed out, a net change of 0 holders.
- The largest AnaptysBio buyer in Q2 2021 was Great Point Partners, an estimated $9.59M added.
- The largest AnaptysBio seller in Q2 2021 was State Street, an estimated $11.5M sold.
Based on aggregated 13F filings for Q2 2021.